Exact Mass: 348.2067248
Exact Mass Matches: 348.2067248
Found 90 metabolites which its exact mass value is equals to given mass value 348.2067248,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
TTNPB
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D000970 - Antineoplastic Agents
Bexarotene
Bexarotene is only found in individuals that have used or taken this drug. It is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposis sarcoma (Wikipedia). Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XF - Retinoids for cancer treatment C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D000970 - Antineoplastic Agents
Roxatidine acetate
C19H28N2O4 (348.20489680000003)
Roxatidine acetate is only found in individuals that have used or taken this drug. It is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked. D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
4-[2-(5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid
bixin aldehyde
Bixin aldehyde is practically insoluble (in water) and an extremely weak basic (essentially neutral) compound (based on its pKa). Bixin aldehyde can be found in a number of food items such as bamboo shoots, sago palm, welsh onion, and globe artichoke, which makes bixin aldehyde a potential biomarker for the consumption of these food products.
2(S)-7-Hydroxy-2-methyl-2-(4-methyl-3-pentenyl)-5-(2-phenylethyl)chromene
2,7,7,10-Tetramethyl-4-pentyl-7H-benzo[c]furo[2,3-f]chromene #
2-(3,7-dimethylocta-2,6-dienyl)-5-(2-phenylethenyl)benzene-1,3-diol
7-Hydroxy-2-methyl-2-(4-methyl-3-penten-1-yl)-5-(2-phenylethyl)-2H-1-benzopyran
Bexarotene
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XF - Retinoids for cancer treatment C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D000970 - Antineoplastic Agents CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6073; ORIGINAL_PRECURSOR_SCAN_NO 6071 CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6096; ORIGINAL_PRECURSOR_SCAN_NO 6094 CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6097; ORIGINAL_PRECURSOR_SCAN_NO 6096 CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6100; ORIGINAL_PRECURSOR_SCAN_NO 6095 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3295
Tobramycin ion source fragment BCX, ring A fission
Roxane
C19H28N2O4 (348.20489680000003)
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
bhas#18
An (omega-1)-hydroxy fatty acid ascaroside that is ascr#18 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans as well as the sour paste nematode, Panagrellus redivivus.
bhos#18
An omega-hydroxy fatty acid ascaroside that is oscr#18 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.
BENZYL 4-((TERT-BUTOXYCARBONYL)(METHYL)AMINO)PIPERIDINE-1-CARBOXYLATE
C19H28N2O4 (348.20489680000003)
(R)-1-Boc-3-(Cbz-amino-methyl)-piperidine
C19H28N2O4 (348.20489680000003)
4-(carboxy-p-tolyl-methyl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester
C19H28N2O4 (348.20489680000003)
Carpindolol
C19H28N2O4 (348.20489680000003)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
TERT-BUTYL 4-(((BENZYLOXY)CARBONYL)AMINO)-4-METHYLPIPERIDINE-1-CARBOXYLATE
C19H28N2O4 (348.20489680000003)
CARBAMIC ACID, [TRANS-4-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]CYCLOHEXYL]-, PHENYLMETHYL ESTER
C19H28N2O4 (348.20489680000003)
Methyl 1-Benzyl-4-(Boc-amino)piperidine-4-carboxylate
C19H28N2O4 (348.20489680000003)
(3-METHYL-PIPERAZIN-1-YL)-PHENYL-METHANONE
C19H28N2O4 (348.20489680000003)
(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ETHYL-AMINE
C19H28N2O4 (348.20489680000003)
benzyl 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]piperidine-1-carboxylate
C19H28N2O4 (348.20489680000003)
1-N-Cbz-4-Boc-(Aminomethyl)piperidine
C19H28N2O4 (348.20489680000003)
2-(4-Boc-piperazinyl)-4-phenylbutanoic acid
C19H28N2O4 (348.20489680000003)
1-Benzyl 4-(2-methyl-2-propanyl) (5R)-5-methyl-1,4-diazepane-1,4-dicarboxylate
C19H28N2O4 (348.20489680000003)
(6aS,10aR)-6,6,9-trimethyl-3-phenethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
(Z)-4-(2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid
(3R,10R)-10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyundecanoic acid
(3R)-11-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyundecanoic acid
9alpha-Fluoro-11beta-hydroxy-4-pregnene-3,20-dione
21-Fluoro-11-hydroxy-pregn-4-ene-3,20-dione, (11beta)-
9-Fluoro-17beta-hydroxy-6alpha,17-dimethylandrost-4-ene-3,11-dione
6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate
2-[(1S,3S,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
C19H28N2O4 (348.20489680000003)
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
C19H28N2O4 (348.20489680000003)
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
C19H28N2O4 (348.20489680000003)
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
C19H28N2O4 (348.20489680000003)
(2R,3S,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-hydroxy-3-[(Z)-2-hydroxyethenoxy]cyclohexyl]oxyoxan-3-ol
[3-(3-Acetyloxy-2-butanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium
[1-Carboxy-3-[2,3-di(propanoyloxy)propoxy]propyl]-trimethylazanium
bixin dialdehyde
An apo carotenoid that is the dialdehyde obtained by reduction of the terminal methyl ester and carboxy groups of bixin.
BDP9066
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.